CG Invites (A083790) Stock Overview
A biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
A083790 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
CG Invites Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩990.00 |
| 52 Week High | ₩1,985.00 |
| 52 Week Low | ₩760.00 |
| Beta | -0.010 |
| 1 Month Change | 10.00% |
| 3 Month Change | -25.23% |
| 1 Year Change | -44.29% |
| 3 Year Change | -75.25% |
| 5 Year Change | -87.23% |
| Change since IPO | -87.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| A083790 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.0% | -8.7% | -4.3% |
| 1Y | -44.3% | 0.5% | 146.8% |
Return vs Industry: A083790 underperformed the KR Biotechs industry which returned 6.9% over the past year.
Return vs Market: A083790 underperformed the KR Market which returned 148.4% over the past year.
Price Volatility
| A083790 volatility | |
|---|---|
| A083790 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in KR Market | 16.7% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A083790 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A083790's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 73 | Joong-Myung Cho | www.cgxinc.com |
CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The company is also involved in the development of Ivaltinostat, an anti-cancer drug, currently under phase 2 stage for the treatment of pancreatic cancer and myelodysplastic syndrome, as well as preclinical stage for the treatment of acute myeloid leukemia and hepatocellular carcinoma; Camrelizumab, an anti-cancer drug, currently under phase 3 stage for the treatment of NSCLC; and Luxeptinib, an anti-cancer drug, currently under phase 1 stage for the treatment of acute myeloid leukemia, chronic lymphocytic leukemia, and non-hodgkin’s lymphoma.
CG Invites Co., Ltd. Fundamentals Summary
| A083790 fundamental statistics | |
|---|---|
| Market cap | ₩76.13b |
| Earnings (TTM) | -₩4.12b |
| Revenue (TTM) | ₩29.22b |
Is A083790 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A083790 income statement (TTM) | |
|---|---|
| Revenue | ₩29.22b |
| Cost of Revenue | ₩33.78b |
| Gross Profit | -₩4.56b |
| Other Expenses | -₩442.24m |
| Earnings | -₩4.12b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -53.59 |
| Gross Margin | -15.61% |
| Net Profit Margin | -14.10% |
| Debt/Equity Ratio | 48.6% |
How did A083790 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 08:07 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CG Invites Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| JooYong Kim | Bookook Securities Co. Ltd |
| Jae Hoon Shin | LS Securities Co., Ltd. |
| Hyun-Tae Kim | Mirae Asset Securities Co., Ltd. |